Black Book’s ad hoc survey of 200 healthcare executives reveals real-time disruptions, cost inflation, and stalled innovation as Trump-era tariffs expand across key healthcare imports.
Industry groups hoping to lessen impacts of Donald Trump’s “Liberation Day” plans on medical products and MedTech development sent letter to the U.S. Trade Representative.
Solventum purification and filtration portfolio expected to be highly complementary with Thermo Fisher’s bioproduction business, strengthening the company in the high growth bioprocessing market.
Teleflex to create a new, independent publicly traded company consisting of its Urology, Acute Care, and OEM businesses. Remaining units and recently announced acquisition expected to remain.
FDA-Cleared Nanotechnology developed by Nanovis is planned for use to enhance Medtronic PEEK interbody fusion devices used in Spine Surgery.
Bridgefield Capital will buy the segment, which includes cardiac resuscitation and emergency care devices, for an undisclosed amount.
Stryker has agreed to sell its US spine implant business to Viscogliosi Brothers with plans to create a newly formed company called VB Spine, LLC. The deal also includes a binding offer for Stryker’s French spine business, and the company said it plans to sell its spine implants businesses in other international markets.
With a new executive order to leave the World Health Organization, the Make America Healthy Again (MAHA) movement is driving new policy and promises for faster time to market for product innovation. MedTech start-ups are keen to capitalize on the opportunity, yet funding to push product through early product phases – concept and design through clinical studies and post-market surveillance – can be complex. Daniele Viappiani of GC1 Ventures offers strategies for MedTech start-ups to find the right investors.
Acquisition expected to strengthen Stryker’s neurovascular business with Inari VTE product portfolio including mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism.
“Tariffs may have negative consequences for a continually growing market due to an aging population and the increasing prevalence of long-term illnesses. Companies will be forced to increase prices to make up for losses incurred by the proposed tariffs which may cause supply chain disruptions.”
